Enhancing the choice and use of medicines: An overview of the Medicines Authority’s strategy to empower patients and consumers and support healthcare professionals

1 Gavril Flores BA, CYM, MA
2 Patricia Vella Bonanno BPharm(Hons), MSc, PhD

Public health authorities regulate in the public interest to protect health, ensure patient access to safe medicines, stimulate innovation and encourage a competitive market.1 Pharmaceutical regulation supports various components of a national pharmaceutical policy, including research and development (through regulation of clinical trials and provision of scientific advice), authorisation of medicinal products, regulation of the supply chain (manufacturers, wholesale dealers and pharmacies), pharmacovigilance and the rational use of medicinal products (through information about medicinal products and the use of medicines). The tangible public health outcomes of these processes are access, availability and affordability of medicinal products which are of good quality, and safe and efficacious when used rationally.

The preamble of Directive 2001/83/EC stipulates that prescribers and pharmacists must have access to neutral, objective sources of information about products available on the market.2 The Pharmaceutical Forum (2007) presents ten core quality principles on information to patients on diseases and treatment options. These are objective and unbiased information, evidence-based, reliable, accessible, relevant and appropriate, patient oriented, up to date, understandable, transparent, and consistent with statutory information.3 Coulter and Ellins (2007) argue that a number of patient focused quality interventions can be taken to engage patients in their own or their family’s individual care, including improving health literacy, clinical decision-making, self-care and patient safety.4

One of the objectives of the Medicines Authority is to provide objective and unbiased information on medicinal products. This is done in a number of ways including the evaluation of the labelling on medicinal products, approval of the information on the patient information leaflet (PIL) and of the Summary of Product Characteristics (SPC) and the publication of the list of authorised medicines and the approved PIL and SPC on its website.

The Authority set a communications strategy and activities were planned. The first priority was to make information about medicines accessible to healthcare professionals and to patients and consumers. In 2010-2011 a specific national set of initiatives entitled ‘Know Your Medicines’ which were mainly targeted at patients and consumers were carried out. The initiatives were aimed at informing patients and consumers about medicines thus supporting and empowering them to participate in decisions for the choice of their medicines and to use their medicines rationally. The initiatives were based on a need analysis carried out between September 2010 and January 2011.

An analysis of public knowledge and use of medicines

A needs analysis was carried out with the aim of identifying the public’s knowledge about medicines, awareness on the medicines lifecycle, trust in medicines and awareness on choice and use of medicines. Two hundred telephone interviews were conducted over a period of five months, between September 2010 and January 2011. A stratified sample of five hundred people was used based on gender, age and locality. Therefore the response rate was of 40%. The interviews were conducted
Key points

- The Medicines Authority has a public health remit to provide objective and unbiased information on medicinal products.
- A total of 66% of participants of a study conducted by the Medicines Authority seek advice or information before taking non-prescription medicine for the first time while 12% never seek advice or information. Over 85% of participants do not know the difference between innovator and generic medicines. Most participants use the internet as a source of information on medicines and 3% of respondents said that they bought medicine over the internet, claiming wider selection, convenience and price as the main reasons for doing this.
- The Medicines Authority launched the ‘Know Your Medicines’ Initiatives to empower patients and consumers and support healthcare professionals in the choice and use of medicines.

Activities carried out as part of the communications strategy

The results of the study were assessed to ensure that the information provided and the initiatives undertaken are in line with the needs of the general population. A National Initiative entitled ‘Know Your Medicines’ was launched in January 2011 to support healthcare professionals, patients and consumers on the choice and use of medicines. The initiatives included:

1. The development of the Malta Medicines List (www.maltamedicineslist.com) as a source of information on all authorised medicines. The list includes advance searching and filtering functionalities and links to Summary of Product Characteristics and Package Leaflets.
2. A specific webpage with targeted information for patients and consumers (www.knowyourmedicines.com). Both websites will be integrated in a new website on medicines with enhanced features.
3. Active participation in traditional media through articles, interviews and programs and the use of social online (e.g. Facebook) to reach different age groups.
4. Two widely distributed information leaflets in Maltese and English languages. One of the leaflets has a question and answer format in line with the gaps identified through the needs analysis and another leaflet presented information on innovator and generic medicines and a section on falsified medicines.
5. Development of a Know Your Medicines Helpline.
6. SMS and e-mail notifications for information related to safety and quality of medicines.
7. Delivery of continuous professional development sessions for pharmacists organised by the Malta College of Pharmacy Practice and participation in sessions for pharmacists organised by the Malta Chamber of Pharmacists.
8. Collaboration with other regulators and the Consumers Affairs Council to organise information sessions specifically targeted to consumers.
9. Information meetings about legislation in collaboration with the Malta EU Action Steering Committee.
10. Papers for local and international journals, including an article on the first Seven Years of EU Pharmaceutical Legislation in Malta on the WHO Drug Information Journal.5

Way forward

The Medicines Authority will continue with the implementation of its communications strategy and the next step is the provision of targeted information based on the needs of specific stakeholders (healthcare professionals, patients and consumers and industry). A new website incorporating advanced features and with information targeted for different stakeholder groups will be launched in the following months. Moreover the initiatives taken to date will be evaluated.

The Medicines Authority is grateful to all health care professionals and associations for their collaboration, particularly in reviewing and distributing the information material, feedback and recommendations for further development and for future communication and information initiatives is welcome.

References